Check out your Company Bowl for anonymous work chats.
Shionogi Announces FDA Approval of FETROJA® (Cefiderocol) for the Treatment of Hospital-Acquired Bacterial Pneumonia and Ventilator-Associated Bacterial
New AMR Action Fund steps in to save collapsing antibiotic pipeline with pharmaceutical industry investment of US$1 billion
FDA Accepts Shionogi’s Supplemental New Drug Application with Priority Review for FETROJA® (cefiderocol) for the Treatment of Hospital-Acquired Bacterial Pneumonia and Ventilator-Associated Bacterial Pneumonia
OSAKA, Japan & FLORHAM PARK, N.J.–(BUSINESS WIRE)– In response to the novel coronavirus (SARS-CoV-2), Shionogi & Co., Ltd. (hereafter “Shionogi”), a pharmaceutical company with a major focus on infectious diseases, has joined the ranks of pharmaceutical companies across the globe and is working with public institutions, academia and partner companies in the following efforts to fight against COVID-19.
FETROJA® (cefiderocol) Approved by the FDA for Treatment of Complicated Urinary Tract Infections (cUTI) in Adult Patients with Limited or No Alternative Treatment Options Visit Our Newsroom to Learn More: http://glassdoor.com/slink.htm?key=vMLa8
Pivotal Trial Results for Shionogi’s Cefiderocol Published in the Lancet Infectious Diseases Visit Our Newsroom to Learn More: http://glassdoor.com/slink.htm?key=vQStV
Baloxavir Marboxil Phase II and III Studies for the Treatment of Influenza Published in the New England Journal of Medicine Visit Our Newsroom to Learn More: http://glassdoor.com/slink.htm?key=vQkHu
Shionogi Announces U.S. Availability of Mulpleta® (Lusutrombopag) for the Treatment of Thrombocytopenia in Adults with Chronic Liver Disease Scheduled to Undergo a Procedure Visit Our Newsroom to Learn More: http://glassdoor.com/slink.htm?key=vQQVy
Shionogi Announces FDA Approval of Mulpleta® (Lusutrombopag) Visit our Newsroom to Learn More: http://glassdoor.com/slink.htm?key=vQQVc
